{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:51:25Z","timestamp":1790124685999,"version":"4.0.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802596"],"award-info":[{"award-number":["81802596"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai","doi-asserted-by":"publisher","award":["20ZR1408900"],"award-info":[{"award-number":["20ZR1408900"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The role of nicotinamide N-methyltransferase (NNMT) in ovarian cancer is still elusive. Our aim is to explore the expression of NNMT in ovarian cancer and to assess its association with patient prognosis and treatment response.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We first analyzed the differential expression of NNMT among fallopian tube epithelium, primary ovarian cancers, metastatic ovarian cancers, and recurrent ovarian cancers using Gene Expression Ominus (GEO) database (GSE10971, GSE30587, GSE44104 and TCGA datasets). Then, we assessed the association of NNMT expression with clinical and molecular parameters using CSIOVDB database and GSE28739 dataset. Next, we evaluate the association of NNMT expression with the prognosis of ovarian cancer patients in both GSE9891 dataset and TCGA dataset. Finally, GSE140082 dataset was used to explore the association of NNMT expression with bevacizumab response.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>NNMT expression was significantly elevated in lymphovascular space invasion (LVSI)-positive ovarian cancers compared with that in LVSI-negative ovarian cancers (TCGA dataset, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05), Moreover, increased expression of NNMT was associated with increased tumor stage, grade, and mesenchymal molecular subtype (CSIOVDB database). Survival analysis indicated that increased expression of NNMT was associated with a reduced OS in both GSE9891 dataset (HR: 2.28, 95%CI: 1.51\u20133.43, Log-rank <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and TCGA dataset (HR: 1.55, 95%CI: 1.02\u20132.36, Log-rank <jats:italic>P<\/jats:italic>\u2009=\u20090.039). Multivariate analysis further confirmed the negative impact of NNMT expression on OS in ovarian cancer patients in those two datasets. Furthermore, the NNMT-related nomogram showed that NNMT shared a larger contribution to OS, compared with debulking status. More interestingly, bevacizumab conferred significant improvements in OS for patients with low NNMT expression (HR: 0.56, 95%CI: 0.31\u20130.99, Log-rank <jats:italic>P<\/jats:italic>\u2009=\u20090.049). In contrast, patients with high NNMT expression didn\u2019t benefit from bevacizumab treatment significantly (HR: 0.85, 95%CI: 0.48\u20131.49, Log-rank <jats:italic>P<\/jats:italic>\u2009=\u20090.561). NNMT expression was positively correlated with the expression of genes, LDHA and PGAM1, involved in Warburg effect.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In conclusion, NNMT expression is associated with the aggressive behavior of ovarian cancer, correlates with a poor prognosis, and is predictive of sensitivity to bevacizumab treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-07785-w","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T13:02:53Z","timestamp":1610629373000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Patients with low nicotinamide N-methyltransferase expression benefit significantly from bevacizumab treatment in ovarian cancer"],"prefix":"10.1186","volume":"21","author":[{"given":"Jun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiran","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6498-5609","authenticated-orcid":false,"given":"Xiaohong","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,14]]},"reference":[{"issue":"4","key":"7785_CR1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/nrclinonc.2013.5","volume":"10","author":"RL Coleman","year":"2013","unstructured":"Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol. 2013;10(4):211\u201324.","journal-title":"Nat Rev Clin Oncol"},{"issue":"20","key":"7785_CR2","doi-asserted-by":"publisher","first-page":"14835","DOI":"10.1016\/S0021-9258(17)36700-5","volume":"269","author":"S Aksoy","year":"1994","unstructured":"Aksoy S, Szumlanski CL, Weinshilboum RM. Human liver nicotinamide N-methyltransferase. cDNA cloning, expression, and biochemical characterization. J Biol Chem. 1994;269(20):14835\u201340.","journal-title":"J Biol Chem"},{"issue":"18","key":"7785_CR3","doi-asserted-by":"publisher","first-page":"6550","DOI":"10.1158\/1078-0432.CCR-05-0983","volume":"11","author":"M Roessler","year":"2005","unstructured":"Roessler M, Rollinger W, Palme S, Hagmann ML, Berndt P, Engel AM, et al. Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer. Clin Cancer Res. 2005;11(18):6550\u20137.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"7785_CR4","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s00432-009-0563-y","volume":"135","author":"M Tomida","year":"2009","unstructured":"Tomida M, Mikami I, Takeuchi S, Nishimura H, Akiyama H. Serum levels of nicotinamide N-methyltransferase in patients with lung cancer. J Cancer Res Clin Oncol. 2009;135(9):1223\u20139.","journal-title":"J Cancer Res Clin Oncol"},{"key":"7785_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1756-9966-28-20","volume":"28","author":"J Kim","year":"2009","unstructured":"Kim J, Hong SJ, Lim EK, Yu YS, Kim SW, Roh JH, et al. Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis. J Exp Clin Cancer Res. 2009;28:20.","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"7785_CR6","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/ijc.10631","volume":"101","author":"H Kassem","year":"2002","unstructured":"Kassem H, Sangar V, Cowan R, Clarke N, Margison GP. A potential role of heat shock proteins and nicotinamide N-methyl transferase in predicting response to radiation in bladder cancer. Int J Cancer. 2002;101(5):454\u201360.","journal-title":"Int J Cancer"},{"issue":"52","key":"7785_CR7","doi-asserted-by":"publisher","first-page":"6679","DOI":"10.1038\/onc.2008.264","volume":"27","author":"Y Wu","year":"2008","unstructured":"Wu Y, Siadaty MS, Berens ME, Hampton GM, Theodorescu D. Overlapping gene expression profiles of cell migration and tumor invasion in human bladder cancer identify metallothionein 1E and nicotinamide N-methyltransferase as novel regulators of cell migration. Oncogene. 2008;27(52):6679\u201389.","journal-title":"Oncogene"},{"issue":"2","key":"7785_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1093\/carcin\/bgq225","volume":"32","author":"SW Tang","year":"2011","unstructured":"Tang SW, Yang TC, Lin WC, Chang WH, Wang CC, Lai MK, et al. Nicotinamide N-methyltransferase induces cellular invasion through activating matrix metalloproteinase-2 expression in clear cell renal cell carcinoma cells. Carcinogenesis. 2011;32(2):138\u201345.","journal-title":"Carcinogenesis"},{"issue":"5","key":"7785_CR9","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/nchembio.1204","volume":"9","author":"OA Ulanovskaya","year":"2013","unstructured":"Ulanovskaya OA, Zuhl AM, Cravatt BF. NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink. Nat Chem Biol. 2013;9(5):300\u20136.","journal-title":"Nat Chem Biol"},{"issue":"9","key":"7785_CR10","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1158\/1078-0432.CCR-16-1323","volume":"23","author":"K Palanichamy","year":"2017","unstructured":"Palanichamy K, Kanji S, Gordon N, Thirumoorthy K, Jacob JR, Litzenberg KT, et al. NNMT silencing activates tumor suppressor PP2A, inactivates oncogenic STKs, and inhibits tumor forming ability. Clin Cancer Res. 2017;23(9):2325\u201334.","journal-title":"Clin Cancer Res"},{"key":"7785_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.abb.2014.08.017","volume":"564","author":"X Xie","year":"2014","unstructured":"Xie X, Yu H, Wang Y, Zhou Y, Li G, Ruan Z, et al. Nicotinamide N-methyltransferase enhances the capacity of tumorigenesis associated with the promotion of cell cycle progression in human colorectal cancer cells. Arch Biochem Biophys. 2014;564:52\u201366.","journal-title":"Arch Biochem Biophys"},{"issue":"16","key":"7785_CR12","doi-asserted-by":"publisher","first-page":"26200","DOI":"10.18632\/oncotarget.15429","volume":"8","author":"J Kanska","year":"2017","unstructured":"Kanska J, Aspuria PP, Taylor-Harding B, Spurka L, Funari V, Orsulic S, et al. Glucose deprivation elicits phenotypic plasticity via ZEB1-mediated expression of NNMT. Oncotarget. 2017;8(16):26200\u201320.","journal-title":"Oncotarget"},{"issue":"7758","key":"7785_CR13","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41586-019-1173-8","volume":"569","author":"MA Eckert","year":"2019","unstructured":"Eckert MA, Coscia F, Chryplewicz A, Chang JW, Hernandez KM, Pan S, et al. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature. 2019;569(7758):723\u20138.","journal-title":"Nature"},{"issue":"8","key":"7785_CR14","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/mc.23209","volume":"59","author":"Y Cui","year":"2020","unstructured":"Cui Y, Yang D, Wang W, Zhang L, Liu H, Ma S, et al. Nicotinamide N-methyltransferase decreases 5-fluorouracil sensitivity in human esophageal squamous cell carcinoma through metabolic reprogramming and promoting the Warburg effect. Mol Carcinog. 2020;59(8):940\u201354.","journal-title":"Mol Carcinog"},{"issue":"41","key":"7785_CR15","doi-asserted-by":"publisher","first-page":"43843","DOI":"10.18632\/oncotarget.5983","volume":"6","author":"TZ Tan","year":"2015","unstructured":"Tan TZ, Yang H, Ye J, Low J, Choolani M, Tan DS, et al. CSIOVDB: a microarray gene expression database of epithelial ovarian cancer subtype. Oncotarget. 2015;6(41):43843\u201352.","journal-title":"Oncotarget"},{"issue":"1","key":"7785_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13048-019-0524-2","volume":"12","author":"J Li","year":"2019","unstructured":"Li J, Yue H, Yu H, Lu X, Xue X. Development and validation of SIRT3-related nomogram predictive of overall survival in patients with serous ovarian cancer. J Ovarian Res. 2019;12(1):47.","journal-title":"J Ovarian Res"},{"issue":"7","key":"7785_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.","journal-title":"Nucleic Acids Res"},{"key":"7785_CR18","doi-asserted-by":"publisher","first-page":"40714","DOI":"10.1038\/srep40714","volume":"7","author":"A Mobley","year":"2017","unstructured":"Mobley A, Zhang S, Bondaruk J, Wang Y, Majewski T, Caraway NP, et al. Aurora kinase a is a biomarker for bladder cancer detection and contributes to its aggressive behavior. Sci Rep. 2017;7:40714.","journal-title":"Sci Rep"},{"issue":"3","key":"7785_CR19","first-page":"649","volume":"6","author":"C Chen","year":"2016","unstructured":"Chen C, Wang X, Huang X, Yong H, Shen J, Tang Q, et al. Nicotinamide N-methyltransferase: a potential biomarker for worse prognosis in gastric carcinoma. Am J Cancer Res. 2016;6(3):649\u201363.","journal-title":"Am J Cancer Res"},{"issue":"29","key":"7785_CR20","doi-asserted-by":"publisher","first-page":"45837","DOI":"10.18632\/oncotarget.9962","volume":"7","author":"X Xie","year":"2016","unstructured":"Xie X, Liu H, Wang Y, Zhou Y, Yu H, Li G, et al. Nicotinamide N-methyltransferase enhances resistance to 5-fluorouracil in colorectal cancer cells through inhibition of the ASK1-p38 MAPK pathway. Oncotarget. 2016;7(29):45837\u201348.","journal-title":"Oncotarget"},{"issue":"15","key":"7785_CR21","doi-asserted-by":"publisher","first-page":"19975","DOI":"10.18632\/oncotarget.7891","volume":"7","author":"Y Xu","year":"2016","unstructured":"Xu Y, Liu P, Zheng DH, Wu N, Zhu L, Xing C, et al. Expression profile and prognostic value of NNMT in patients with pancreatic cancer. Oncotarget. 2016;7(15):19975\u201381.","journal-title":"Oncotarget"},{"issue":"6","key":"7785_CR22","doi-asserted-by":"publisher","first-page":"9672","DOI":"10.18632\/oncotarget.14192","volume":"8","author":"J Li","year":"2017","unstructured":"Li J, Li S, Chen R, Lu X. Increased risk of poor survival in ovarian cancer patients with high expression of SNAI2 and lymphovascular space invasion. Oncotarget. 2017;8(6):9672\u201385.","journal-title":"Oncotarget"},{"issue":"7","key":"7785_CR23","doi-asserted-by":"publisher","first-page":"C444","DOI":"10.1152\/ajpcell.00188.2015","volume":"309","author":"TL Yeung","year":"2015","unstructured":"Yeung TL, Leung CS, Yip KP, Au YC, Wong ST, Mok SC. Cellular and molecular processes in ovarian cancer metastasis. A review in the theme: cell and molecular processes in Cancer metastasis. Am J Physiol Cell Physiol. 2015;309(7):C444\u201356.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"7785_CR24","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1186\/s12885-019-6470-y","volume":"19","author":"H Yue","year":"2019","unstructured":"Yue H, Wang J, Chen R, Hou X, Li J, Lu X. Gene signature characteristic of elevated stromal infiltration and activation is associated with increased risk of hematogenous and lymphatic metastasis in serous ovarian cancer. BMC Cancer. 2019;19(1):1266.","journal-title":"BMC Cancer"},{"issue":"26","key":"7785_CR25","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484\u201396.","journal-title":"N Engl J Med"},{"issue":"26","key":"7785_CR26","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473\u201383.","journal-title":"N Engl J Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-07785-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-021-07785-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-07785-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T13:08:43Z","timestamp":1610629723000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-07785-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,14]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["7785"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-07785-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,14]]},"assertion":[{"value":"8 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All data in this article are obtained from published studies, which have received ethics approval and consent to participate. The study was performed in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}